Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ASX:VSL
ASX:VSLMetals and Mining

Vulcan Steel H1 2026 Margin Compression Challenges Bullish Growth Narrative

Vulcan Steel (ASX:VSL) has reported its H1 2026 results with total revenue of NZ$455.2 million and basic EPS of NZ$0.0497, alongside trailing 12 month revenue of NZ$990.5 million and EPS of NZ$0.1097. The company has seen revenue move from NZ$500.3 million and EPS of NZ$0.1056 in H2 2024 to NZ$492.99 million and EPS of NZ$0.0698 in H1 2025, before landing at the latest half year numbers, giving investors a clear view of how the top line and per share earnings have tracked across recent...
NYSE:RDDT
NYSE:RDDTInteractive Media and Services

Is Reddit (RDDT) Offering An Opportunity After Its Sharp Year To Date Share Price Slide?

If you are wondering whether Reddit's current share price lines up with its underlying value, you are not alone, and that is exactly what this article will unpack for you. Reddit recently closed at US$142.46, with a 2% gain over the last 7 days but declines of 34.9% over 30 days and 41.1% year to date, which may signal changing expectations and risk perceptions around the stock. Recent headlines have focused on Reddit's role in online communities and its position among US media and social...
ASX:YAL
ASX:YALOil and Gas

How Will Yancoal’s 2025 Dividend Decision Shape Its Capital Allocation Story (ASX:YAL)?

Yancoal Australia has scheduled a board meeting on 25 February 2026 to approve its audited 2025 financial results and decide on a potential final dividend, alongside other corporate matters. The session will also reconfirm the current board composition, highlighting the governance framework behind decisions on capital allocation, disclosure and shareholder returns. We’ll now examine how the upcoming decision on a potential final dividend shapes Yancoal Australia’s broader investment...
NasdaqGS:CRUS
NasdaqGS:CRUSSemiconductor

Cirrus Logic Insider Sales Follow Record Earnings And Premium Valuation Concerns

Cirrus Logic executives, including EVP Justin E. Dougherty, recently reported significant insider share sales. The transactions followed the company posting record net income and strong earnings per share. These clustered insider moves come as Cirrus Logic (NasdaqGS:CRUS) trades around $142.95. Cirrus Logic (NasdaqGS:CRUS) is in focus after record net income and strong earnings per share were followed by insider selling from multiple senior leaders. The share price sits at about $142.95,...
NYSE:TWLO
NYSE:TWLOIT

A Look At Twilio’s Valuation After Earnings, Profitability Return And Share Repurchase Progress

Why Twilio’s latest earnings matter for shareholders Twilio (TWLO) has just reported fourth quarter and full year 2025 results, returned to full year profitability, issued new 2026 revenue guidance, and completed a sizable share repurchase tranche. For investors, that combination of reported revenue growth, a shift to full year net income, and ongoing buybacks creates a fresh moment to reassess what the current share price implies about Twilio’s long term potential and risks. See our latest...
NYSE:WELL
NYSE:WELLHealth Care REITs

Welltower (WELL) Valuation Check After Morgan Stanley’s Renewed Confidence And Senior Housing Expansion

Morgan Stanley’s renewed confidence in Welltower (WELL), backed by comments on 2025 performance, new business lines such as private funds management and Tech Quad, and heavy senior housing acquisitions, has put the stock firmly in focus for investors. See our latest analysis for Welltower. The recent guidance for 2026 net income, the long-running dividend track record and heavy acquisition activity appear to be feeding into sentiment. A 14.08% 1 month share price return and a 41.54% 1 year...
TSX:FM
TSX:FMMetals and Mining

First Quantum Minerals Updates Taca Taca Outlook And Valuation Debate

First Quantum Minerals (TSX:FM) has released a new NI 43-101 technical report for its Taca Taca copper gold molybdenum project in Argentina. The report outlines a higher project value, larger reserves, and updated economics for what the company presents as its next major development asset. First Quantum Minerals, trading at CA$38.31, has seen its share price move up 5.8% over the past week and 2.7% year to date, while the 1 year return sits at 116.8%. The new Taca Taca report arrives...
NasdaqGS:ACHC
NasdaqGS:ACHCHealthcare

Assessing Acadia Healthcare (ACHC) After A 57% One-Year Share Price Decline

If you are wondering whether Acadia Healthcare Company is attractively priced or still a value trap after a tough run, this breakdown is designed to give you a clear view of where the stock stands today. The shares last closed at US$17.38, with returns of 3.6% over 7 days, 14.1% over 30 days, 21.6% year to date, but a 57.3% decline over 1 year and a 78.4% decline over 3 years. This raises questions about how the current price lines up with underlying value. Recent news coverage has largely...
TSX:AG
TSX:AGMetals and Mining

A Look At First Majestic Silver (TSX:AG) Valuation After Record Q4 Results And Dividend Policy Change

First Majestic Silver (TSX:AG) is back in the spotlight after record Q4 2025 earnings and revenue, a swing from the prior year’s loss, along with higher silver production and a richer dividend policy. See our latest analysis for First Majestic Silver. The recent string of announcements, including the richer dividend policy, completion of a share buyback tranche and record Q4 results, has coincided with a powerful move in the stock, with a 90 day share price return of 124.26% and a 1 year...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Assessing Novo Nordisk (CPSE:NOVO B) Valuation After Recent Share Price Weakness

Why Novo Nordisk (CPSE:NOVO B) is on investors’ radar today Novo Nordisk (CPSE:NOVO B) has drawn fresh attention after recent share price weakness, with the stock showing negative returns over the past week, month, past 3 months, year to date and past year. See our latest analysis for Novo Nordisk. With the share price at DKK244.25, Novo Nordisk’s 30 day share price return of 39.14% and 1 year total shareholder return of 61.76% suggest momentum has faded recently compared with earlier gains...
NYSE:GEV
NYSE:GEVElectrical

GE Vernova’s AI Power Supercycle And The Test For New Payouts

GE Vernova (NYSE:GEV) is entering what management describes as a new growth supercycle, supported by surging power demand from AI data centers. The company reports a 65% jump in orders and aims to expand an already large $150b backlog. Recent capital allocation moves include doubling the dividend and authorizing a sizable share buyback program. GE Vernova comes into this shift with strong recent share performance, with the stock up 26.4% over the past month and 163.9% over the past year,...
NYSE:RDW
NYSE:RDWAerospace & Defense

A Look At Redwire (RDW) Valuation After Insider Selling And Rising Defense Tensions

Insider selling and geopolitical tensions put Redwire (RDW) in focus A large share sale by Red Holdings, a private equity backer and director at Redwire (RDW), alongside rising geopolitical tensions and potential U.S. military action, has put the space and defense contractor in the market spotlight. See our latest analysis for Redwire. Recent trading reflects this cross-current of insider selling and rising defense interest, with a 50.1% 90 day share price return giving way to a 35.1% 30 day...
NasdaqGS:CPRT
NasdaqGS:CPRTCommercial Services

Assessing Copart (CPRT) Valuation After Recent Share Price Weakness And Undervaluation Signals

Recent share performance and business context Copart (CPRT) shares have pulled back recently, with a 1 day return of around a 3% decline, and weaker performance over the past week, month, and past 3 months drawing fresh attention from investors. The company runs online auctions and vehicle remarketing services across multiple countries, processing and selling vehicles over the internet for dismantlers, rebuilders, dealers, exporters, and the public. See our latest analysis for Copart. At a...
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

Credo’s PCIe 6.0 Retimer Milestone Sharpening AI Data Center Focus

Credo Technology Group Holding’s PCIe 6.0-capable Toucan retimer has achieved PCI-SIG compliance, confirming it meets industry standards for the latest PCIe 6.0 technology. The company also introduced new connectivity products, including the Blue Heron 224G AI scale-up retimer and additional PCIe 6.0-capable devices aimed at AI and data center workloads. These launches focus on higher bandwidth and reliability for customers building AI clusters and advanced data center infrastructure. Credo...
NYSE:FIX
NYSE:FIXConstruction

A Look At Comfort Systems USA (FIX) Valuation After Q4 2025 Beat And Record Backlog

Comfort Systems USA (FIX) shares moved sharply after the company released Q4 2025 results featuring revenue and earnings well ahead of market expectations, a record backlog that was nearly double the previous level, and a higher quarterly dividend. See our latest analysis for Comfort Systems USA. Despite a 3.33% decline in the 1 day share price return after the earnings spike, Comfort Systems USA still shows strong momentum, with a 30 day share price return of 26.05% and a very large 5 year...
NYSE:CTRI
NYSE:CTRIConstruction

Is It Too Late To Consider Centuri Holdings (CTRI) After A 72% One-Year Rally?

If you are wondering whether Centuri Holdings' share price still reflects good value, or if the recent excitement has already been priced in, this article will walk you through what the numbers indicate about the stock. The shares last closed at US$31.24, with returns of 0.7% over 7 days, 10.0% over 30 days, 21.0% year to date and 72.1% over the past year. This has naturally raised questions about how the current price compares with underlying value. Recent news flow around Centuri Holdings...
NYSE:BAX
NYSE:BAXMedical Equipment

Is Baxter International (BAX) Pricing In Its Turnaround After Years Of Share Price Weakness?

If you are wondering whether Baxter International's share price reflects its underlying value, this article will walk you through what the current market price might be implying. The stock last closed at US$21.26, with returns of 7.4% over 7 days, 7.2% over 30 days and 9.0% year to date, set against a 38.3% decline over 1 year, 42.8% over 3 years and 69.7% over 5 years. Recent news flow around Baxter International has focused on the company's long term repositioning and ongoing portfolio...
NYSE:PRLB
NYSE:PRLBMachinery

Assessing Proto Labs (PRLB) Valuation After Strong 1 Year Share Price Rebound

What Proto Labs investors can glean from recent performance Proto Labs (PRLB) has moved sharply over the past year, with the stock returning 57.3% and showing double digit gains over the past month and past 3 months, catching the attention of many investors. Alongside that share price performance, the company reports annual revenue of US$533.1 million and net income of US$21.2 million, with recent annual revenue and net income growth rates of 6.4% and 24.4% respectively. See our latest...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

Is It Too Late To Consider O'Reilly Automotive (ORLY) After Strong Multi‑Year Share Gains?

If you are looking at O'Reilly Automotive and wondering whether the current share price still offers value, this article will walk through what the numbers actually say. The stock closed at US$95.35, with returns of 1.4% decline over the last 7 days, 3.9% decline over 30 days, a 5.5% gain year to date, 8.8% over 1 year, 69.1% over 3 years and 217.0% over 5 years. This raises fair questions about how much of the story might already be priced in. Recent coverage has focused on O'Reilly...
ENXTPA:CLARI
ENXTPA:CLARIHealthcare

Clariane (ENXTPA:CLARI) Valuation In Focus As Asset Sales And Debt Reduction Shape 2025 Results Expectations

Upcoming results put asset sales and debt reduction in focus Clariane (ENXTPA:CLARI) is drawing fresh attention as investors look ahead to its 2025 annual results, with ongoing asset disposals and debt reduction efforts identified as key themes for the announcement. See our latest analysis for Clariane. The recent pullback, with a 1 day share price return of a 4.67% decline and a 7 day share price return of a 6.33% decline, comes after a 90 day share price return of a 4.92% gain and a 1 year...
NYSE:SO
NYSE:SOElectric Utilities

Is Southern (SO) Offering Value After Strong Multi Year Share Price Gains

If you are looking at Southern and wondering whether the current share price lines up with its underlying value, you are not alone. Southern's share price recently closed at US$95.18, with returns of 0.2% over 7 days, 8.7% over 30 days, 9.2% year to date, 10.6% over 1 year, 64.5% over 3 years and 98.5% over 5 years shaping how investors are thinking about its potential and risk. Recent coverage of Southern has focused on its position in the US utilities sector and the market's ongoing...
BME:NTGY
BME:NTGYGas Utilities

A Look At Naturgy Energy Group (BME:NTGY) Valuation After Solid 2025 Earnings Results

Earnings trigger and what changed for Naturgy Energy Group Naturgy Energy Group (BME:NTGY) just released full year 2025 results, with sales of €19.455b and net income of €2.023b, compared with €19.267b and €1.901b a year earlier, drawing fresh attention to the stock. See our latest analysis for Naturgy Energy Group. The earnings release comes after a relatively subdued period for the shares. The 7-day share price return is a decline of 2.64% and the 90-day share price return is a decline of...
NYSE:A
NYSE:ALife Sciences

Assessing Agilent Technologies (A) Valuation As Earnings Approach And New FDA Diagnostic Approval Draws Interest

Investor focus on Agilent Technologies (A) is picking up as the life sciences tools company heads into its upcoming earnings report, with attention also on fresh FDA approval for its PD-L1 IHC 22C3 pharmDx companion diagnostic. See our latest analysis for Agilent Technologies. At a share price of $124.20, Agilent’s recent 1 day share price gain contrasts with a 30 day share price return of 8.03% decline and a 1 year total shareholder return of 7.45% decline. This suggests momentum has...
NasdaqGM:VNDA
NasdaqGM:VNDABiotechs

Vanda Pharmaceuticals (VNDA) Is Up 33.8% After FDA Approval Of BYSANTI Atypical Antipsychotic

Vanda Pharmaceuticals recently received U.S. FDA approval for BYSANTI (milsaperidone) tablets, a new atypical antipsychotic for acute manic or mixed episodes in bipolar I disorder and for schizophrenia in adults, with U.S. commercial launch targeted for the third quarter of 2026 and marketing protection expected into 2044. BYSANTI’s status as a new chemical entity that rapidly converts to iloperidone, aligning with Fanapt’s established safety profile while offering dual active molecules,...